Onkologie. 2022:16(3):134-141 | DOI: 10.36290/xon.2022.027

Immunotherapy in non-melanoma skin cancer

Miroslav Důra
Dermatovenerologická klinika, 1. LF UK a VFN, Praha

Antitumoral immunotherapy is a golden standard in modern therapy in the increasing number of metastatic or locally advanced solid tumors. This treatment achieves significant and long-lasting treatment responses and reveals prolongation of progression free survival, overall survival, together with quality-of-life improvement.

In the field of malignant cutaneous tumors, the therapeutic effect of immunotherapy is well-known in metastatic melanoma, in which the immunotherapy became a standard of the modern systemic treatment. The effect of the immunotherapeutic drugs was also established in metastatic and locally advanced non-melanoma skin cancer, namely squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma.

Currently, two monoclonal antibodies with confirmed antitumoral effect in the treatment of non-melanoma skin cancer are available in our conditions, namely cemiplimab and avelumab.

The article presents an overview of these antitumoral drugs and deals with their therapeutic effect, treatment management, mechanism of action and the adverse effects.

Keywords: immunotherapy, cemiplimab, avelumab, squamous cell carcinoma, basal cell carcinoma, Merkel cell carcinoma.

Published: May 16, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Důra M. Immunotherapy in non-melanoma skin cancer. Onkologie. 2022;16(3):134-141. doi: 10.36290/xon.2022.027.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. Eur J Cancer. 2020;128:60-82. Go to original source... Go to PubMed...
    2. Lebbe C, Becker JC, Grob JJ, et al. Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51(16):2396-2403. Go to original source... Go to PubMed...
    3. LIBTAYO, 350MG INF CNC SOL 1X7ML, Státní ústav pro kontrolu léčiv. Státní ústav pro kontrolu léčiv [online]. Copyright © 2001 [cit. 26.03.2022]. Avaible from: https://www.sukl.cz/modules/medication/detail.php?code=0238538&tab=info.
    4. BAVENCIO, 20MG/ML INF CNC SOL 1X10ML, Státní ústav pro kontrolu léčiv. Státní ústav pro kontrolu léčiv [online]. Copyright © 2001 [cit. 26.03.2022]. Avaible from: https://www.sukl.cz/modules/medication/detail.php?kod=0222464.
    5. [online]. Copyright © [cit. 26.03.2022]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_cs.pdf.
    6. D'Angelo SP, Bhatia S, Brohl AS, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. J Immunother Cancer. 2020;8(1):e000674. Go to original source... Go to PubMed...
    7. [online]. Copyright © [cit. 26.03.2022]. Avaible from: https://www.ema.europa.eu/en/documents/product-information/bavencio-epar-product-information_cs.pdf.
    8. Důra M. Cemiplimab. Remedia. 2021;31:455-460. Go to original source...
    9. Arenberger P. Karcinom z Merkelových buněk. Remedia. 2019;29:323-325.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.